This innovative strategy holds therapeutic potential as it was also used for in vivo correction of an hereditary tyrosinemia disorder caused by mutations in the Fah gene, coding for fumarylacetoacetate hydrolase, that results in liver failure (Grompe et al., 1993; Yao et al., 2018). The gene discussed is FAH; the disease is liver failure.